Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 30 results.
User Information
Export Records
  1. 1.   A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals
  2. Cockerham, Leslie R; Yukl, Steven A; Harvill, Kara; Somsouk, Ma; Joshi, Sunil K; Sinclair, Elizabeth; Liegler, Teri; Hoh, Rebecca; Lyons, Sophie; Hunt, Peter W; Rupert, Adam; Sereti, Irini; Morcock, David; Rhodes, Ajantha; Emson, Claire; Hellerstein, Marc K; Estes, Jake; Lewin, Sharon; Deeks, Steven G; Hatano, Hiroyu
  3. Pathogens & Immunity. 2017 2(3): 310-334.
  1. 2.   Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection
  2. Houser, K. V.; Gretebeck, L.; Ying, T.; Wang, Y.; Vogel, L.; Lamirande, E. W.; Bock, K. W.; Moore, I. N.; Dimitrov, D. S.; Subbarao, K.
  3. The Journal of infectious diseases. 2016, 15-May; 213(10): 1557-61.
  1. 3.   Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents
  2. Devkota, L.; Lin, C. M.; Strecker, T. E.; Wang, Y.; Tidmore, J. K.; Chen, Z.; Guddneppanavar, R.; Jelinek, C. J.; Lopez, R.; Liu, L.; Hamel, E.; Mason, R. P.; Chaplin, D. J.; Trawick, M. L.; Pinney, K. G.
  3. Bioorganic & Medicinal Chemistry. 2016, 1-Mar; 24(5): 938-56.
  1. 4.   HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells
  2. Maldarelli, F.; Wu, X.; Su, L.; Simonetti, F. R.; Shao, W.; Hill, S.; Spindler, J.; Ferris, A. L.; Mellors, J. W.; Kearney, M. F.; Coffin, J. M.; Hughes, S. H.
  3. Science. 2014, 11-Jul; 345(6193): 179-83.
  1. 5.   Cancer stem cells: a systems biology view of their role in prognosis and therapy
  2. Mertins, S. D.
  3. Anti-Cancer Drugs. 2014, Apr; 25(4): 353-67.
  1. 6.   Antiviral innate immunity: editorial overview
  2. Freed, E. O.; Gale, M.
  3. Journal of Molecular Biology. 2014, 20-Mar; 426(6): 1129-32.
  1. 7.   The importance of Raf dimerization in cell signaling
  2. Freeman, A. K.; Ritt, D. A.; Morrison, D. K.
  3. Small GTPases. 2013, Jul-Sep; 4(3): 180-5.
  1. 8.   Anthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine
  2. Klinman, D. M.; Yamamoto, M.; Tross, D.; Tomaru, K.
  3. Expert Opinion on Biological Therapy. 2009, Dec; 9(12): 1477-86.
  1. 9.   Intrathoracic nontuberculous mycobacterial infections in otherwise healthy children
  2. Freeman, A. F.; Olivier, K. N.; Rubio, T. T.; Bartlett, G.; Ochi, J. W.; Claypool, R. J.; Ding, L.; Kuhns, D. B.; Holland, S. M.
  3. Pediatric pulmonology. 2009, Nov; 44(11): 1051-6.
  1. 10.   Development of HIF-1 inhibitors for cancer therapy
  2. Onnis, B.; Rapisarda, A.; Melillo, G.
  3. Journal of Cellular and Molecular Medicine. 2009, Sep; 13(9A): 2780-6.
  1. 11.   Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets
  2. Adamson, C. S.; Freed, E. O.
  3. Molecular Interventions. 2009, Apr; 9(2): 70-4.
  1. 12.   RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy
  2. Shao, W.; Kearney, M.; Maldarelli, F.; Mellors, J. W.; Stephens, R. M.; Lifson, J. D.; KewalRamani, V. N.; Ambrose, Z.; Coffin, J. M.; Palmer, S. E.
  3. Retrovirology. 2009 6: 101.
  1. 13.   Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?
  2. Dimitrov, D. S.; Marks, J. D.
  3. Methods in molecular biology (Clifton, N.J.). 2009 525: 1-27, xiii.
  1. 14.   Scaling-up and production of therapeutic antibodies for preclinical studies
  2. Feng, Y.; Dimitrov, D. S.
  3. Methods in molecular biology (Clifton, N.J.). 2009 525: 499-508, xiii.
  1. 15.   IL-15 induces C4+ effector memory T cell production and tissue emigration in nonhuman primates
  2. Picker, L. J.; Reed-Inderbitzin, E. F.; Hagen, S. I.; Edgar, J. B.; Hansen, S. G.; Legasse, A.; Planer, S.; Piatak, M.; Lifson, J. D.; Maino, V. C.; Axthelm, M. K.; Villinger, F.
  3. Journal of Clinical Investigation. 2006, JUN; 116(6): 1514-1524.
  1. 16.   5-Lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking
  2. Catalano, A.; Caprari, P.; Soddu, S.; Procopio, A.; Romano, M.
  3. Faseb Journal. 2004, SEP; 18(12): Published online only.
  1. 17.   The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation
  2. Angeloni, D.; Danilkovitch-Miagkova, A.; Miagkov, A.; Leonard, E. J.; Lerman, M. I.
  3. Journal of Biological Chemistry. 2004 279(5): 3726-3732.
  1. 18.   Transcriptome analysis of mouse stem cells and early embryos
  2. Sharov, A. A.; Piao, Y. L.; Matoba, R.; Dudekula, D. B.; Qian, Y.; Vanburen, V.; Falco, G.; Martin, P. R.; Stagg, C. A.; Bassey, U. C.; Wang, Y. X.; Carter, M. G.; Hamatani, T.; Aiba, K.; Akutsu, H.; Sharova, L.; Tanaka, T. S.; Kimber, W. L.; Yoshikawa, T.; Jaradat, S. A.; Pantano, S.; Nagaraja, R.; Boheler, K. R.; Taub, D.; Hodes, R. J.; Longo, D. L.; Schlessinger, D.; Keller, J.; Klotz, E.; Kelsoe, G.; Umezawa, A.; Vescovi, A. L.; Rossant, J.; Kunath, T.; Hogan, B. L. M.; Curci, A.; D'Urso, M.; Kelso, J.; Hide, W.; Ko, M. S. H.
  3. Plos Biology. 2003 1(3): 410-419.
  1. 19.   HIV-1 induced in the setting of IL-2 therapy is transient and not derived from PBMC proviral reservoirs
  2. Imamichi, H.; Zhang, Y. M.; Kovacs, J.; Dewar, R.; Metcalf, J.; Vogel, S.; Salzman, N.; Lane, H. C.
  3. Conference on Retroviruses and Opportunistic Infections. 1999, 135 (abstract no. 358).
  1. 20.   HIV replication persists in patients receiving HAART despite undetectable plasma virus
  2. Nata Rajan, V. N.; Chun, T. W.; O'Neill, D. P.; Metcalf, J. A.; Mican, J.; Engel, D.; Fauci, A. S.; Lane, H. C.; Kovacs, J. A.
  3. International Conference on AIDS. 1998, 12 341-2.
  1. 21.   Chemistry and anti-retroviral activity of compounds attacking NC zinc fingers
  2. Henderson, L.; Chertova, E.; Ott, D.; Hewes, S.; Casas-Finet, J.; Kane, B.; Johnson, D.; Sowder, R. II; Rossio, J.; Lifson, J.; Arthur, L.
  3. HIV Pathogenesis and Treatment Conference. 1998, 50 (abstract no. 2014).
  1. 22.   High antitumor selectivity of bisimidazoacridones is a function of the aromatic chromophores
  2. Cholody, W. M.; Czerwinski, G.; Michejda, C. J.
  3. Annual Meeting of the American Association for Cancer Research. 1997, 38 A1484.
  1. 23.   Azodicarbonamide (ADA) as an anti-HIV agent that targets the nucleocapsid protein zinc fingers: a clinical candidate
  2. Rice, W. G.; Turpin, J. A.; Summers, M. F.; Covell, D. G.; Sausville, E. A.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 105 (abstract no. 219).
  1. 24.   Application of restriction enzyme analysis to screen drug-resistant mutations in HIV-protease and in proteolytic cleavage sites in the gag region
  2. Vasudevachari, M. B.; Imamichi, T.; Imamichi, H.; Zhang, Y. M.; Salzman, N. P.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 176 (abstract no. 606).
  1. 25.   Emergence of drug resistant HIV variants with mutations in the protease gene and gag cleavage sites during indinavir therapy
  2. Zhang, Y. M.; Imamichi, H.; Falloon, J.; Lane, H. C.; Vasudevachari, M. B.; Imamichi, T.; Salzman, N. P.
  3. Conference on Retroviruses and Opportunistic Infections. 1997, 175 (abstract no. 602).
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel